Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Morphic Holding, Inc. MORF NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • US • USD

SharesGrow Score
38/100
1/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$57.00
+0%

Morphic Holding, Inc. (MORF) is a Biotechnology company in the Healthcare sector, currently trading at $56.99. It has a SharesGrow Score of 38/100, indicating a weak investment profile with 1 out of 7 criteria passed.

Analyst consensus target is MORF = $57 (+0% upside).

Financials: revenue is $521,000, +34.2%/yr average growth. Net income is $152M (loss), growing at -76.6%/yr. Net profit margin is -29192.9% (negative). Gross margin is -109.4% (-45.6 pp trend).

Balance sheet: total debt is $2M against $697M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 28.94 (strong liquidity). Debt-to-assets is 0.3%. Total assets: $723M.

Analyst outlook: 4 / 9 analysts rate MORF as buy (44%) — mixed sentiment.

SharesGrow 7-Criteria breakdown: Value 50/100 (Partial), Growth 58/100 (Partial), Past 0/100 (Fail), Health 100/100 (Pass), Moat 12/100 (Fail), Future 34/100 (Fail), Income 10/100 (Fail).

$57.00
▲ 0.02% Upside
Average Price Target
The 12-month price target for Morphic Holding, Inc. is $57.00.

MORF SharesGrow Score Overview

44/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 50/100
Valuation — P/E, PEG, Forward PEG
GROWTH 58/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 12/100
Gross margin is + market cap
FUTURE 34/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — MORF

~
VALUE Partial
50/100
MORF trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Analyst consensus target is $57, implying +0% from the current price $57. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
~
GROWTH Partial
58/100
MORF: +34.2%/yr revenue is, -76.6%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet MORF: Debt-to-Equity (D/E) ratio 0 (conservative), Current ratio is 28.94 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
12/100
MORF: Gross margin is -109.4% (-45.6 pp trend), $3B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 12/100. ≥ 70 = Pass.
View details →
✗
FUTURE Fail
34/100
Analyst outlook: 4 / 9 analysts rate MORF as buy (44%). Analyst consensus target is $57 (+0% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
MORF: Net profit margin is -29192.9%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range19.345-57.0
Volume1.74M
Avg Volume (30D)2.45M
Market Cap$2.86B
Beta (1Y)1.49
Share Statistics
EPS (TTM)-3.59
Shares Outstanding$42.39M
IPO Date2019-06-27
Employees128
CEOPraveen P. Tipirneni
Financial Highlights & Ratios
Revenue (TTM)$521K
Gross Profit$-570K
EBITDA$-177.6M
Net Income$-152.1M
Operating Income$-178.69M
Total Cash$704.35M
Total Debt$2.34M
Net Debt$-56.23M
Total Assets$722.51M
Price / Earnings (P/E)-15.9
Price / Sales (P/S)5493.87
Analyst Forecast
1Y Price Target$57.00
Target High$57.00
Target Low$57.00
Upside+0.0%
Rating ConsensusHold
Analysts Covering9
Buy 44% Hold 56% Sell 0%
Company Info
CountryUS
ExchangeNASDAQ Global Market
CurrencyUSD
ISINUS61775R1059

Price Chart

Track all markets on TradingView
MORF
Morphic Holding, Inc. ↗  ·  NASDAQ Global Market
Healthcare • Biotechnology
19.35 52WK RANGE 57.00

People Also View

RVMD
RVMD
Revolution Medicines, Inc.
$147.01
+7.86%
 MDGL
MDGL
Madrigal Pharmaceuticals, Inc.
$524.99
-0.13%
 PCVX
PCVX
Vaxcyte, Inc.
$62.76
+1.64%
 ACLX
ACLX
Arcellx, Inc.
$114.89
+0.02%
 PTGX
PTGX
Protagonist Therapeutics, Inc.
$104.72
+7.33%
 TERN
TERN
Terns Pharmaceuticals, Inc.
$52.68
+0.13%
 AKRO
AKRO
Akero Therapeutics, Inc.
$54.65
+0.00%
 VKTX
VKTX
Viking Therapeutics, Inc.
$35.52
+1.46%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message